We demonstrate signs of transient, prediagnostic evidence of autoimmune activity in patients later diagnosed and classified as having type 2 diabetes. Compared with other participants with type 2 diabetes, this subgroup had earlier onset of diabetes and may have lower β-cell function with possible clinical implications (Diabetes Care)
Diabetes News
Tag: Type 2 Diabetes
Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
In contrast to real-world data, there was no evidence of an improvement in all-cause and cardiovascular mortality in type 2 diabetes participants included in control arms of randomised clinical trials across 5 decades. Further studies should investigate whether and how dissimilarities in populations, procedures, and assessments of exposures and outcomes explain the differences between real-world setting and clinical trials (Acta Diabetologica)
Carbohydrate restriction for glycaemic control in Type 2 diabetes: a systematic review and meta‐analysis
There was no overall pooled effect on HbA1c in favour of restricting carbohydrate; however, restriction of carbohydrate to 50–130 g per day had beneficial effects on HbA1c in trials up to 6 months (Diabetic Medicine)
Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes
We concluded that recovery of the AIR could be obtained in T2DM patients of varying disease duration by short-term intensive insulin therapy and it could be conveniently estimated using posttreatment fasting plasma glucose and other fasting indicators (Journal of Diabetes Research)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes
SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure (The Lancet)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure (NEJM)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years (JAMA)
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)
Renal biomarkers informing various aspects of kidney function may further our understanding of the complex interplay between diabetic kidney disease and cardiovascular disease (American Journal of Cardiology)
Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross‐over trial
People with type 2 diabetes experienced improved postprandial and 24 h glycaemia and decreased blood pressure after 4 months of AA supplementation when compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to improve glycaemic and blood pressure control in people with type 2 diabetes (Diabetes, Obesity and Metabolism)
Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycemia (Diabetes, Obesity and Metabolism)
Efficacy of a self-management education programme on patients with type 2 diabetes in primary care: A randomised controlled trial
HbA1c reductions are difficult to obtain in adequately controlled patients. On the other hand, raising awareness on one´s disease can increase disease control self-efficacy. This finding, accompanied by reduced medication consumption and healthcare use rates, highlights that usual care would be benefited by incorporating certain SDSMP aspects (Primary Care Diabetes)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Lixisenatide reduces progression of UACR in macroalbuminuric patients, and is associated with a lower risk of new-onset macroalbuminuria after adjustment for baseline and on-trial HbA 1c and other traditional renal risk factors (The Lancet Diabetes & Endocrinology)
Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
These data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus (Hypertension)
Evaluation of the Long‐Term Cost‐Effectiveness of Once‐Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK
Compared with treatment with dulaglutide, once‐weekly semaglutide represents a cost‐effective option for treating people with T2DM not achieving glycaemic control on metformin in the UK, projected to both improve clinical outcomes and reduce costs (Diabetes, Obesity and Metabolism)
Development and validation of a risk prediction model for severe hypoglycemia in adult patients with type 2 diabetes
This 14-variable prediction model for SH events may be a useful tool to identify high-risk patients and guide prevention of SH in adult patients with T2DM (Clinical Epidemiology)
Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial
Compared with CPT, IPT reduced HbA 1c in patients with type 2 diabetes and moderate-to-severe periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis could be important for effective management of type 2 diabetes (The Lancet Diabetes & Endocrinology)
Self-monitoring of blood glucose provides no important benefit for most people with type 2 diabetes
The review supports current guideline recommendations that self-monitoring is not routinely used for people with type 2 diabetes controlled on diet or tablets (NIHR)
Long‐term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second‐line Type 2 diabetes mellitus treatment in a US Veterans Affairs population
The results of the present study may inform decisions on whether to augment or discontinue metformin; when considering the long‐term risks, switching to a sulfonylurea appears unfavourable compared with other therapies. Instead, adding a thiazolidinedione to existing metformin therapy appears to be superior to adding or switching to a sulfonylurea (Diabetic Medicine)
A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
In conclusion, short-term intensive therapy with basal insulin plus OHAs showed comparable benefits to CSII in terms of overall glycemic control and improvement in β-cell function in newly diagnosed patients with type 2 diabetes mellitus and is a possible option for treating newly diagnosed patients with type 2 diabetes (Journal of Diabetes Research)
Effect of Health Information Technologies on Glycemic Control Among Patients with Type 2 Diabetes
Our meta-analysis shows that overall, HITs have favorable impact on glycemic control of patients with type 2 diabetes. On average, mobile-based interventions produce larger effects compared to other forms of approaches under review (Current Diabetes Reports)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 34
- Next Page »
Glycosmedia is also available as an App: